Ellen T. Matloff, MS
Ellen T. Matloff, MS, is a research scientist in the Department of Genetics and the director of cancer genetic counseling at Yale Cancer Center/Yale School of Medicine in New Haven, Connecticut.
List of faculty who participated in PCOC 2013
Amy Berman, BS, RN
As a senior program officer for The John A. Hartford Foundation, Amy Berman, BS, RN, has devoted her career to spreading the word about better ways to deliver healthcare.
Peter B. Bach, MD, MAPP
To begin the session entitled Oncology Practice in the Era of PCMHs and ACOs: Square Pegs or Round Holes?¯, Peter B. Bach, MD, MAPP, outlined how new payment models are changing the settings of oncology practice.
Cliff Goodman, PhD; Amy Berman, BS, RN; Dennis Scanlon, PhD; and Manasi A. Tirodkar, PhD, MS,
Cliff Goodman, PhD, senior vice president and principal, The Lewis Group, moderated the panel discussion, The Role of Consumerism in the Deliverability of Care.¯
Ethan Basch, MD
How patients feel during treatment for cancer can have a lot to do with outcomes-and
with the cost of care.
Cliff Goodman, PhD; A. Mark Fendrick, MD; John L. Fox, MD, MHA; and Ira M. Klein, MD, MBA, FACP
Cliff Goodman, PhD, moderated a panel discussion on the Implications of Healthcare Reform: 'No' Will Be Heard.¯
Lee N. Newcomer, MD, MHA
Lee N. Newcomer, MD, MHA, senior vice president for Oncology, Genetics and Women's Health at UnitedHealthcare, spoke on Defining and Measuring Quality Outcomes in Oncology.¯
Lee N. Newcomer, MD, MHA; Phyllis Torda; Dennis Scanlon, PhD; Ira M. Klein, MD, MBA, FACP
Lee N. Newcomer, MD, MHA, joined the response panel, Challenges and Opportunities for Quality Measures in Oncology.¯
Bruce A. Feinberg, DO
Bruce A. Feinberg, DO, of Cardinal Health Specialty Solutions, published results in Evidence-Based Oncology1 showing that Cardinal's deployment of pathways had achieved measurable savings across a diverse set of healthcare providers, with an actuary's validation.
Karen Lewis, MS, MM, CGC
Precision Medicine, examined how care targeted at the individual can hold down costs while improving quality. This includes matching the right drug to the right patient, and genetic testing is a tool for doing that.
Ira M. Klein, MD, MBA, FACP; Jan Berger, MD, MJ; Michael A. Kolodziej, MD
Moving beyond the topic, Companion Diagnostics in Targeted Treatment, the panel took on the unregulated nature of testing in the wake of the June 2013 US Supreme Court ruling against Myriad Genetics, which ended the company's BRCA testing monopoly.
What will next-generation sequencing look like? How will the use of data make its way into clinical care?
Lee N. Newcomer, MD, MHA; Michael A. Kolodziej, MD; John L. Fox, MD, MHA; Ira M. Klein, MD, MBA, FACP
A lively discussion on Foundation Medicine's approach to creating genomic profiles.
Scott D. Ramsey, MD, PhD
From his vantage point as director of the Cancer Technology Assessment Group at the Fred Hutchinson Cancer Research Center in Seattle, Washington, Scott D. Ramsey, MD, PhD,sees the financial fallout of cancer care like few do.
Michael E. Chernew, PhD; Cliff Goodman, PhD; Jeffrey D. Dunn, PharmD, MBA; Kirby Eng, RPh
Data about escalating prices for cancer drugs laid the groundwork for the panel that followed, where Michael E. Chernew, PhD, Harvard health economist and co-editor-in-chief of The American Journal of Managed Care, outlined how changing the paradigm will require a different kind of shopping.
John L. Fox, MD, MHA; Bo Gamble; and Cliff Goodman, PhD
How can pharmaceutical companies adapt to a changing environment? Are they the source of the problem, or have they simply responded to US Food and Drug Administration mandates?